Anna Svedberg1, Svante Vikingsson1,2, Anders Vikström3, Niels Hornstra4, Magnus Kentson5,6, Eva Branden7,8, Hirsh Koyi7,8, Bengt Bergman9, Henrik Gréen1,2. 1. Clinical Pharmacology, Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 2. Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden. 3. Department of Pulmonary Medicine, Linköping University Hospital, Linköping, Sweden. 4. Department of Pulmonary Medicine, Kalmar County Hospital, Kalmar, Sweden. 5. Division of Medicine, Department of Pulmonary Medicine, Ryhov Hospital, Jönköping, Sweden. 6. Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 7. Department of Respiratory Medicine, Gävle Hospital, Gävle, Sweden. 8. Centre for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden. 9. Department of Respiratory Medicine and Allergology, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Abstract
AIMS: Erlotinib is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer highly metabolized by the cytochrome P450 (CYP) 3A. Hence, CYP3A4 activity might be a useful predictor of erlotinib pharmacokinetics in personalized medicine. The effect of erlotinib on CYP3A activity was therefore studied in non-small cell lung cancer patients. METHODS: The study included 32 patients scheduled for erlotinib monotherapy. CYP3A activity was assessed using quinine as a probe before and during erlotinib treatment. Plasma from blood samples drawn 16 hours post quinine administration were analysed using HPLC with fluorescence detection to determine the quinine/3-OH-quinine ratio. RESULTS: Matched samples, available from 13 patients, showed an induction of CYP3A activity (P = 0.003, Wilcoxon's signed rank test) after 2 months of treatment. The quinine/3-OH-quinine ratio decreased from 20.2 (± 13.4) at baseline to 11.0 (± 4.34). Single-point samples, available from 19 patients, supported the decrease in ratio (P = 0.007, Mann-Whitney U-test). Generally, females had a higher CYP3A activity both at baseline and after two months of treatment. Statistical analysis by gender also showed significant increase in CYP3A activity (males, n = 10, P = 0.001, and females, n = 22, P = 0.001). CONCLUSIONS: An induction of CYP3A activity was observed after 2 months of erlotinib treatment which was also seen when subdividing based on gender. It could be important to take this into consideration for patients co-administering other CYP3A-metabolizing drugs during erlotinib treatment and also makes it difficult to use baseline CYP3A activity to predict erlotinib pharmacokinetics.
AIMS: Erlotinib is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer highly metabolized by the cytochrome P450 (CYP) 3A. Hence, CYP3A4 activity might be a useful predictor of erlotinib pharmacokinetics in personalized medicine. The effect of erlotinib on CYP3A activity was therefore studied in non-small cell lung cancerpatients. METHODS: The study included 32 patients scheduled for erlotinib monotherapy. CYP3A activity was assessed using quinine as a probe before and during erlotinib treatment. Plasma from blood samples drawn 16 hours post quinine administration were analysed using HPLC with fluorescence detection to determine the quinine/3-OH-quinine ratio. RESULTS: Matched samples, available from 13 patients, showed an induction of CYP3A activity (P = 0.003, Wilcoxon's signed rank test) after 2 months of treatment. The quinine/3-OH-quinine ratio decreased from 20.2 (± 13.4) at baseline to 11.0 (± 4.34). Single-point samples, available from 19 patients, supported the decrease in ratio (P = 0.007, Mann-Whitney U-test). Generally, females had a higher CYP3A activity both at baseline and after two months of treatment. Statistical analysis by gender also showed significant increase in CYP3A activity (males, n = 10, P = 0.001, and females, n = 22, P = 0.001). CONCLUSIONS: An induction of CYP3A activity was observed after 2 months of erlotinib treatment which was also seen when subdividing based on gender. It could be important to take this into consideration for patients co-administering other CYP3A-metabolizing drugs during erlotinib treatment and also makes it difficult to use baseline CYP3A activity to predict erlotinib pharmacokinetics.
Authors: Hilary Calvert; Chris Twelves; Malcolm Ranson; Ruth Plummer; Scott Fettner; Michael Pantze; Jie Ling; Marta Hamilton; Bert L Lum; Ashok Rakhit Journal: Anticancer Drugs Date: 2014-08 Impact factor: 2.248
Authors: Marcello Tiseo; Roberta Andreoli; Francesco Gelsomino; Paola Mozzoni; Cinzia Azzoni; Marco Bartolotti; Beatrice Bortesi; Matteo Goldoni; Enrico Maria Silini; Giuseppe De Palma; Antonio Mutti; Andrea Ardizzoni Journal: Lung Cancer Date: 2013-12-12 Impact factor: 5.705
Authors: Linda Björkhem-Bergman; Tobias Bäckström; Hanna Nylén; Yuko Rönquist-Nii; Eva Bredberg; Tommy B Andersson; Leif Bertilsson; Ulf Diczfalusy Journal: Drug Metab Pharmacokinet Date: 2014-02-11 Impact factor: 3.614
Authors: Ulf Diczfalusy; Jun Miura; Hyung-Keun Roh; Rajaa A Mirghani; Jane Sayi; Hanna Larsson; Karl G Bodin; Annika Allqvist; Mary Jande; Jong-Wook Kim; Eleni Aklillu; Lars L Gustafsson; Leif Bertilsson Journal: Pharmacogenet Genomics Date: 2008-03 Impact factor: 2.089
Authors: Michael Steffens; Tanusree Paul; Vivien Hichert; Catharina Scholl; Dirk von Mallek; Christoph Stelzer; Fritz Sörgel; Bärbel Reiser; Christian Schumann; Stefan Rüdiger; Stefan Boeck; Volker Heinemann; Volker Kächele; Thomas Seufferlein; Julia Stingl Journal: Eur J Cancer Date: 2016-01-25 Impact factor: 9.162